Gabapentin and Lyrica (pregabalin) are not recommended to be taken together. Clinical guidelines consistently advise against combining these two medications because they work through the same mechanism in the body, making the combination pharmacologically redundant while increasing the risk of side effects. Some doctors have prescribed them together in specific cases, but this falls outside standard practice.
Why These Two Drugs Are Redundant
Gabapentin and pregabalin both belong to a class called gabapentinoids. Despite being designed as analogs of a brain chemical called GABA, their actual pain-relieving effect comes from binding to the same molecular target on nerve cells: a specific subunit of calcium channels involved in transmitting pain signals. Research has confirmed this subunit is the sole target responsible for the analgesic effects of both drugs. When a pain signal travels along a nerve, these calcium channels help release chemical messengers that carry the signal forward. Both gabapentin and pregabalin block this process in the same way.
Because the two drugs compete for the same binding site, taking both doesn’t give you two different treatments. It gives you two versions of the same treatment, with overlapping effects and compounded side effects. This is why pain management guidelines from NICE and other bodies list gabapentin and pregabalin as alternatives to each other, not partners. If one doesn’t work, the recommendation is to switch to the other, or to a different class of medication entirely, such as certain antidepressants.
How They Differ Despite Working the Same Way
Though they share a mechanism, gabapentin and pregabalin are not identical drugs. Pregabalin is absorbed more quickly and more completely. It reaches peak levels in your blood within about an hour, compared to three hours for gabapentin. Pregabalin’s bioavailability (the percentage of the drug that actually enters your bloodstream) exceeds 90%, while gabapentin’s ranges from just 30% to 60%.
This gap exists because gabapentin relies on specific transport molecules in the small intestine that become saturated at higher doses. Once those transporters are full, additional gabapentin simply passes through without being absorbed. Pregabalin doesn’t have this limitation. It uses additional transport pathways and is also absorbed in the upper part of the large intestine, giving it more predictable, dose-proportional effects. This pharmacokinetic advantage is one reason a doctor might switch someone from gabapentin to pregabalin, but it’s not a reason to take both.
The standard conversion when switching is a 6:1 ratio. For example, if you’re taking 1,800 mg of gabapentin daily, the roughly equivalent pregabalin dose would be 300 mg daily. This ratio is widely used in clinical practice and appears in NHS prescribing guidance.
Respiratory and CNS Depression Risks
The FDA issued a warning in 2019 about serious breathing problems associated with gabapentinoids, particularly when combined with other substances that depress the central nervous system. Both drugs independently slow breathing to some degree. Gabapentin alone has been shown to increase pauses in breathing during sleep, and pregabalin alone can measurably depress respiratory function.
When either drug is combined with other CNS depressants (opioids, benzodiazepines, alcohol, or sedating medications), the breathing suppression is additive. In an FDA review of adverse event reports from 2012 to 2017, 49 cases of gabapentinoid-related respiratory depression were identified, and 12 of those resulted in death. Every fatal case involved at least one additional risk factor: either an underlying respiratory condition or the use of another CNS depressant.
Combining two gabapentinoids doubles down on this risk without a clear therapeutic benefit. People with conditions like COPD, sleep apnea, or age-related decline in lung function face elevated danger. The FDA’s guidance is clear: even when prescribing a single gabapentinoid alongside another CNS depressant, the starting dose should be as low as possible.
What Guidelines Recommend Instead
Major neuropathic pain guidelines treat gabapentin and pregabalin as interchangeable first-line options, not as drugs to be stacked. NICE guidelines recommend offering one of four initial treatments for neuropathic pain: amitriptyline, duloxetine, gabapentin, or pregabalin. If the first choice doesn’t work or causes intolerable side effects, you try one of the remaining three. The approach is sequential, not additive.
For combination therapy, the evidence points toward pairing a gabapentinoid with a drug from a different class. One guideline notes that venlafaxine (an antidepressant) may be added to gabapentin for a better response in diabetic nerve pain. This makes pharmacological sense because the two drugs target different pathways in the pain signaling system, rather than competing for the same one.
A small study of 15 patients with postherpetic neuralgia (nerve pain from shingles) did document the real-world practice of combining gabapentin and pregabalin. The authors explicitly noted that this combination is not recommended by treatment guidelines, though some limited literature has explored it. This represents an off-label, off-guideline use that remains uncommon and unsupported by robust evidence.
Switching Safely Between Gabapentin and Pregabalin
If your doctor decides to switch you from one to the other, the transition needs to be managed carefully. Gabapentinoids should not be stopped abruptly after chronic use. Withdrawal symptoms can appear within one to two days of sudden discontinuation and may include anxiety, insomnia, nausea, sweating, and in severe cases, confusion and blood pressure spikes. These symptoms can resemble alcohol or benzodiazepine withdrawal.
In one documented case, a patient who had used gabapentin for five years was tapered off over just one week. She developed worsening symptoms starting the day after her last dose, culminating in severe mental status changes, chest pain, and dangerously high blood pressure ten days later. The recommended approach is a gradual taper over weeks to months, similar to how benzodiazepines are reduced. Your prescriber will typically overlap the taper of one drug with the introduction of the other to maintain pain control throughout the transition.